AbbVie Named to S&P 500 Dividend Aristocrat Index

Mon Jan 21, 2013 9:58am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130121:nPnCG45364


NORTH CHICAGO, Ill.,  Jan. 21, 2013  /PRNewswire/ -- AbbVie (NYSE: ABBV), a
global biopharmaceutical company, has been named to the S&P 500 Dividend
Aristocrat Index for 2013.

The Dividend Aristocrat Index measures the performance of dividend-paying
companies within the S&P 500 Index that have followed a policy of increasing
dividends each year for at least 25 consecutive years.  In 2013, only 54
companies, approximately 11 percent of companies named to the S&P 500 Index,
were included in this year's update.   

"AbbVie is honored to be included among the premier dividend-paying companies
which are represented by this Index," said  Bill Chase, executive vice president
and chief financial officer, AbbVie. "AbbVie is committed to delivering
attractive shareholder returns through a strong and sustainable dividend which
we intend to grow in the future."

AbbVie was included as a result of the Index's change in its treatment of
spin-off companies.  AbbVie was also named to the S&P High Yield Dividend
Aristocrats Index, which measures the performance of companies within the S&P
Composite 1500 that have followed a policy of increasing dividends each year for
at least 20 consecutive years.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013
following separation from Abbott. With its 125-year history, the company's
mission is to use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address some of the
world's most complex and serious diseases. In 2013, AbbVie employs approximately
21,000 people worldwide and markets medicines in more than 170 countries. For
further information on the company and its people, portfolio and commitments,
please visit  www.abbvie.com. Follow  @abbvie  on Twitter or view careers on our
 Facebook or  LinkedIn  page.

 

SOURCE  AbbVie


Media, Adelle Infante, +1-847-938-8745; Investors, Liz Shea, +1-847-935-2211

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.